Cytena(Exit) Exit

cytena's single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with high viability and proof of clonality without cross-contamination risks.

Management

Jonas Schoendube (M.Sc. | CEO)

Andre Gross (Dipl.-Ing. | CTO)

Benjamin Steimle (Dipl.-Vw. | CFO)

Dr. Peter Koltay (Dipl. Phys. | Business Development)

Pressemeldungen

EUR 3 million in series A for the growth and development of Cytena GmbH

The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the…
Read

cytena, a University of Freiburg spin-off, received EUR 1.1 million of seed capital from HTGF and a private investor

cytena GmbH, headquartered in Freiburg, has developed a device called single-cell printer to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product…
Read

cytena, a University of Freiburg spin-off, received EUR 1.1 million of seed capital from HTGF and a private investor

cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand…
Read

Info & Contact

Benjamin Steimle
Phone:
0049 761 203 732 19
Andre Gross
Phone:
0049 761 203 732 57
Web:
www.cytena.com

Address

Georges-Koehler-Allee 103
79110 Freiburg

In portfolio

13. Apr 2015 – 05. Aug 2019
Exit